William C. Jennings increased his holding by 20.94% to a total of $2.20. In addition to William C. Jennings, 11 other SPNC executives reported Buy trades in the last month.
Based on Spectranetics` latest earnings report from June 30, the company posted quarterly revenue of $61.68M and GAAP net loss of $7.22M. In comparison, last year the company earned revenue of $43.56M and had a GAAP net loss of $6.57M. The company has a one year high of $37.04 and a one year low of $15. Currently, Spectranetics has an average volume of 173.7k.
Seven different firms, including Canaccord Genuity and Dougherty, currently also have a Buy rating on the stock.
Looking at blogger coverage of SPNC, there is a 100% Bullish tendency on the stock, in relation to a 67% average bullish tendency within the Healthcare sector.
Over the last 3 months, the insider sentiment on Spectranetics has been positive based on 47 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.
The Spectranetics Corp develops, manufactures, markets and distributes single-use medical devices. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart and to remove pacemaker and defibrillator cardiac leads.